Cancer Vaccine Partnering Agreements

Reportbuyer.com just published a new market research report: Cancer Vaccine Partnering Agreements.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

London (PRWEB) December 05, 2013

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer vaccine partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer vaccine partnering contract documents
Top cancer vaccine deals by value

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 500 links to online copies of actual cancer vaccine deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of cancer vaccine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer vaccine dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.It also provides the number of deals entered by top 50 big pharma and most active dealmakers in cancer vaccine partnering.

Chapter 3 provides a review of the leading cancer vaccine deals since 2007. Deals are listed by headline value, signed by big pharma and big biotech. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive and detailed review of cancer vaccine partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes adjuvant deals and alliances.

The report also includes numerous tables and figures that illustrate the trends and activities in cancer vaccine partnering and dealmaking since 2007. This report comes with an additional appendix containing entire list of cancer vaccine dealmakers by Company A-Z, deal type and stage of development.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer vaccine technologies and products.

Report scope

Cancer Vaccine Partnering Agreements is intended to provide the reader with an in-depth understanding and access to cancer vaccine trends and structure of deals entered into by leading companies worldwide.

Cancer Vaccine Partnering Agreements includes:

Trends in cancer vaccine dealmaking in the biopharma industry since 2007
Analysis of cancer vaccine deal structure
Access to headline, upfront, milestone and royalty data
Access to over 200 cancer vaccine deal records
The leading cancer vaccine deals by value since 2007
Includes adjuvant and drug delivery deals and alliances since 2007

In Cancer Vaccine Partnering Agreements, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific oncology therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Cancer Vaccine Partnering Agreements report provides comprehensive access to available deals and contract documents for over 500 cancer vaccine deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in cancer vaccine dealmaking
2.1. Introduction
2.2. Cancer vaccine partnering over the years
2.3. Bigpharma cancer vaccine dealmaking activity
2.4. Most active in cancer vaccine partnering
2.5. Cancer vaccine partnering by deal type
2.6. Cancer vaccine partnering by stage of development
2.7. Cancer vaccine partnering by cancer indication
2.8. Disclosed deal terms for cancer vaccine partnering
2.8.1 Cancer vaccine partnering headline values
2.8.2 Cancer vaccine deal upfront payments
2.8.3 Cancer vaccine deal milestone payments
2.8.4 Cancer vaccine royalty rates
2.9. The anatomy of cancer vaccine partnering
2.9. The anatomy of a cancer vaccine deal
2.9.a. Case study 1: Stemline Therapeutics, University of Pittsburgh- March 30 2012
2.9.b. Case study 2: University of Pennsylvania- VGX Pharmaceuticals: April 24, 2007
Chapter 3 – Leading cancer vaccine deals
3.1. Introduction
3.2. Top cancer vaccine deals by value
Chapter 4 – Cancer vaccine dealmaking directory
4.1. Introduction
4.2. Company A-Z
3M
Adamis Pharmaceuticals
Adjuvantix
AdnaGen
Aduro BioTech
Advaxis
Affitech
Agenus Bio
Aldevron
Alexis Biotech
Alligator Bioscience
Alnylam Pharmaceuticals
AnGes MG
Antigen Express
Antigenics
Argos Therapeutics
Ariad Pharmaceuticals
Arizona State University
Astrimmune
Australian Centre for Vaccine Development
Avantogen Oncology
AVAX Technologies
Averion
Bavarian Nordic
Bayer Innovation
Baylor College
Baylor College of Medicine
Baylor Research Institute
Beijing Genomics Institute (BGI)
Bellicum Pharmaceuticals
Berlex
Beth Israel Deaconess Medical Center
Binex
BinnoPharm
Bio-Matrix Scientific
BioAlliance Pharma
Biomira
BioSante Pharmaceuticals
BioVest
BioWa
BN ImmunoTherapeutics
Brigham Young University
Bristol-Myers Squibb
Broadvector
BT Pharma
Cadila Pharmaceuticals
Cancer Research and Prevention Institute of Texas
Cancer Research Institute
Cancer Research Technology
Cancer Research UK
Cancer Research Wales
Cancer Treatment Centers of America
Cardiff University
Catherex
Cedars-Sinai Medical Center
Cell Genesys
Celldex Therapeutics
Celltrion
CG Therapeutics
Champions Oncology
ChemRar High-Tech Center
City of Hope
Clinipace Worldwide
Cobra Biologics
Colby Pharmaceuticals
CSIRO
CSL
CureLab Oncology
CureVac
Cyto Pulse Sciences
Cytos
Daiichi Sankyo
Dalton Pharma Services
Dana-Farber Cancer Institute
Delta-Vir
Dendreon
Department of Defense
Diosynth
Dynavax Technologies
EMD Serono
Encorium Group
Entest BioMedical
Favrille
Federal Ministry of Education and Research (BMBF)
Formatech
Fraunhofer Institute for Cell Therapy and Immunology
Fred Hutchinson Cancer Research Center
G-Con
Galena Biopharma
Genentech
Generex Biotechnology
Genetic Immunity
GenoLac
Genomic Expression
German Cancer Research Center
German Ministry for Education and Research
GlaxoSmithKline
Government of United Kingdom
Gradalis
Hawaii Biotechnology
HemaCare
HemispheRx Biopharma
Henderson Morley
IBio
Ichor Medical Systems
IDIS Pharma
Immatics Biotechnologies
Immune Design
ImmuneRegen BioSciences
ImmunoCellular Therapeutics
Immunomedics
Immunotope
Immunovaccine
ImmunoVaccine Technologies
Immunovo
ImmuRx
Inovio Biomedical
Inovio Pharmaceuticals
Institut Pasteur
IRX Therapeutics
ISSI-Strategy
Jaiva Technologies
Jantibody Therapeutics
Japan Vaccine
Jennerex
Johns Hopkins University
JSC Binnopharm
Juvaris BioTherapeutics
KAEL-GemVax
Karolinska Institute
KellBenx
Kirin Pharma
Kyowa Hakko Kirin
Lipoxen
London Genetics
Ludwig Institute for Cancer Research
MabVax Therapeutics
Mary Crowley Cancer Research Center
Maxcyte
Mayo Clinic
MD Anderson Cancer Center
MDxHealth
Medarex
MediGene
MedImmune
Memorial Sloan Kettering Cancer Center
Merck & Co
Merck KGaA
Merck Serono
Merix Bioscience
Methodist Hospital Research Institute
MorphoSys
Mount Sinai School of Medicine
Natco Pharmaceuticals
National Cancer Institute
National Cancer Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health
National Research Council Canada
NeoStem
NewVac
Northwest Biotherapeutics
Norwegian Research Council
Novartis
Novavax
Numoda
NYU Langone Medical Center
Ohio State University
Omnimmune
OncoMethylome
OncoPep
Oncotherapy Science
Oncothyreon
Oncovir
Ono Pharmaceutical
Onyvax
Opsona Therapeutics
Oxford BioMedica
Oxford Immunotec
PDS Biotechnology
Pepscan Therapeutics
Pevion
Pfenex
Pfizer
Pharmexa
Pharmsynthez
Pique Therapeutics
Pro-Cure Therapeutics
Progenitor Cell Therapy
Prostate Cancer Foundation (PCF)
PsiOxus Therapeutics
Public Health Service
Qiagen
Radboud University Nijmegen Medical Centre
Radient Pharmaceuticals
Roche
RXi Pharmaceuticals
Saint Savas Cancer Hospital
Sanofi-Aventis
SBI Biotech
Scancell
Scripps Research Institute
Serum Institute of India
SOTIO
Stellar Biotechnologies
Stellar Pharmaceuticals
Stemline Therapeutics
Symphony Dynamo
Systems Biology Worldwide
Takeda Pharmaceutical
TapImmune
Tasly Pharmaceuticals
Technomark Life Sciences
Teva Pharmaceuticals
The Regents of the University of California
Therinject
ToleRx
Torrey Pines Institute for Molecular Studies
Transgene
UK Government
UK Technology Strategy Board
University of Chicago
University of Connecticut
University of Copenhagen
University of Florida
University of Liege
University of North Carolina
University of Pennsylvania
University of Pennsylvania School of Veterinary Medicine
University of Pittsburgh
University of Queensland
University of Washington
Uppsala University
Vaccibody
Vaccinogen
Vaxil BioTherapeutics
Vaximm
VGX Pharmaceuticals
ViroMed
Vivalis
VLST Corporation
Wistar Institute
Wittycell
Wuxi Apptec Laboratory Services
Xencor
4.3. By stage of development
Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory
4.4. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Material transfer
Option
Research
Settlement
Sub-license
Supply
Technology transfer
Termination
Warranty
4.5. By oncology therapy area
Oncology
4.6. By related technology
Adjuvant
Vaccines
Chapter 5 –Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Appendices
Appendix 1 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form – Therapy Reports
Order Form – Reports

Table of Figures

Figure 1: Cancer vaccine partnering since 2007
Figure 2: Bigpharma – top 50 – cancer vaccine deals 2007 to 2013
Figure 3: Big pharma cancer vaccine deal frequency – 2007 to 2013
Figure 4: Active cancer vaccine dealmaking activity– 2007 to 2013
Figure 5: Cancer vaccine partnering by deal type since 2007
Figure 6: Cancer vaccine partnering by stage of development since 2007
Figure 7: Vaccine partnering by oncology target since 2007
Figure 8: Cancer vaccine deals with a headline value – by stage of development
Figure 9: Cancer vaccine deal headline value – median value by stage of development
Figure 10: Cancer vaccine deals with upfront payment values – by stage of development
Figure 11: Cancer vaccine deal upfront payment value – median value by stage of development
Figure 12: Cancer vaccine deals with milestone payment – by stage of development
Figure 13: Cancer vaccine deals with royalty rates-by stage of development
Figure 14: Components of the typical cancer vaccine deal structure
Figure 15: Top cancer vaccine deals by value since 2007
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

Companies Mentioned

Abbott, Actavis, Watson Pharmaceuticals, Actelion, Allergan, Amgen, Aspen Pharmacare, Astellas, AstraZeneca, Pfizer, Novartis, GSK, Takeda, Bayer, Boehringer Ingelheim

Read the full report:

Cancer Vaccine Partnering Agreements

http://www.reportbuyer.com/pharma_healthcare/deals_alliances/cancer_vaccine_partnering_agreements.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com/


Contact

  • Sarah Smith
    Research Advisor at Reportbuyer.com
    +44 208 816 85 48
    Email